United Therapeutics Corporation Stock News

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

You'll often hear people say that bear markets are great for finding bargains, and that's true. With the exception of energy, every major sector is in the red for the year.

UTHR vs. ESALY: Which Stock Is the Better Value Option?

United Therapeutics is profitable with 5 FDA approved drugs on the market. The company has strong, double-digit revenue and earnings growth.

UTHR vs. CORT: Which Stock Is the Better Value Option?

United Therapeutics (UTHR) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

United Therapeutics Corporation (NASDAQ:UTHR ) Q3 2022 Earnings Conference Call November 2, 2022 9:00 AM ET Company Participants Dewey Sedman – Head-Investor Relations Martine Rothblatt – Chairper

United Therapeutics (UTHR) delivered earnings and revenue surprises of 37.92% and 4.68%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

SILVER SPRING, Md.

SILVER SPRING, Md.

ASRT vs. UTHR: Which Stock Is the Better Value Option?

United Therapeutics (UTHR) initiates a second phase III study evaluating its Tyvaso inhalation solution. The study will be conducted in sites outside the United States and Canada.

Tyvaso is being explored by United Therapeutics Corporation in the TETON program (two phase 3 studies) which will determine if label expansion for idiopathic pulmonary fibrosis can be achieved. Tyvaso

August 10, 2022 -- InvestorsHub NewsWire --NetworkNewsWire Editorial Coverage: In medicine, there is a term called "clinical inertia," or the case of what someone doesn't know — or what they ignore — could kill them. Simply put, it means failing to start or intensify a therapy when appropriate, which leads to advanced or chronic disease. It is particularly appropriate with a silent killer such as hypertension, a condition that all too often goes untreated, becoming a culprit in morbidity and mor...

United Therapeutics Corporation (NASDAQ:UTHR ) Q2 2022 Results Conference Call August 3, 2022 9:00 AM ET Company Participants Dewey Steadman - Head, IR Dr. Martine Rothblatt - Chairperson, CEO Michael